CAMBRIDGE, UK—A new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui and colleagues from the Cancer Research UK Cambridge Institute, University of Cambridge, report in the New England Journal of Medicine that circulating tumour DNA is a more powerful marker of breast cancer progression than using blood tests for cancer cells or antigens, and raises the possibility of screening the effectiveness of drugs in days rather than months needed to wait for a change in radiological appearance.
You may also like...
Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer 12 Feb, 2014 Video: Txt2Stop: Text Messaging Doubled Smoking Quit Rates 5 Jul, 2011 Salvage Prostate High-Dose-Rate Brachytherapy: Effective and Safe after External Beam Radiotherapy 12 May, 2015 ASCO Audio Journal of Oncology – July 15th 2006 15 Jul, 2006
- Previous story Circulating free tumour DNA test could guide breast cancer therapy
- Next story Two-step immunotherapy brings promise in advanced ovarian cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014